carboplatin (KAR-boh-pla-tin) is a drug used to treat advanced ovarian cancer that has never been treated or has come back after treatment with other anticancer drugs. It is also being studied in the treatment of other types of cancer. Carboplatin is a form of the anticancer drug cisplatin and causes fewer side effects. It damages the cell’s DNA and may kill cancer cells. It is a type of platinum compound.
Information about Carboplatin
Carboplatin is an intravenously administered platinum coordination complex and alkylating agent which is used as a chemotherapeutic agent for the treatment of various cancers, mainly ovarian, head and neck and lung cancers.
Liver safety of Carboplatin
Carboplatin therapy is associated with a low rate of transient serum aminotransferase elevations and with rare instances of clinically apparent liver injury.
Mechanism of action of Carboplatin
Carboplatin (kar" boe pla' tin) is a cisplatin analog with a carboxy-cyclobutane moiety instead of the chloride atoms which makes it more stable and perhaps less toxic than cisplatin. Carboplatin and cisplatin act as alkylating agents causing cross linking between and within DNA strands, leading to inhibition of DNA, RNA and protein synthesis and the triggering of programmed cell death, mostly in rapidly dividing cells. Carboplatin was approved for use in cancer chemotherapy in the United States in 1989. It is currently indicated for advanced ovarian carcinoma, but is also used in other solid tumors including lung and head and neck cancer.
Dosage and administration for Carboplatin
Carboplatin is available in a powder or aqueous solution for injection in 50, 150 and 450 mg amounts generically and under the brand name Paraplatin.
Side effects of Carboplatin
The platinum coordinating complexes have similar toxicities, including nausea and vomiting, diarrhea, bone marrow suppression, as well as neuro-, oto- and nephrotoxicity. They are also mutagenic, teratogenic and carcinogenic. Carboplatin is somewhat better tolerated than cisplatin.